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Abstract 
It took almost 60 years for peritoneal dialysis (PD) to be used widely for the long-term 
treatment of end-stage renal disease. Technical innovations resulted in a significant 
reduction in therapy-related complications, allowing patients to be maintained on PD for 
longer periods of time. More recently, there has also been a greater decrease in mortality 
for patients treated with PD compared to in-center hemodialysis such that the two 
modalities now provide equivalent patient survival. In parallel, changes in public policy have 
spurred an unprecedented expansion in the use of PD in several parts of the world. Our 
understanding of the molecular mechanisms involved in solute and water transport across 
the peritoneum has expanded leading to the identification of potential therapeutic targets 
for improving efficiency of PD.  The pathobiology of structural and functional changes in the 
peritoneum with long-term PD has also been clarified providing new targets for 
intervention. As with hemodialysis, almost half of all deaths on PD occur because of 
cardiovascular events and there is great interest in identifying modality-specific factors 
contributing to the high risk for cardiovascular events. Tremendous progress has been made 
in developing interventions that substantially reduce the risk of PD-related peritonitis. Yet, 
the gains have been unequal primarily because of unequal application of knowledge from 
research into clinical practice.  The work to date has further highlighted the areas in need 
for innovation as we continue to strive to improve the health and outcomes of patients 
treated with PD. 
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The first attempt to use the human peritoneum to dialyze uremic retention solutes 
was made almost one hundred years ago1. Over the next five decades, the therapy gradually 
evolved with an expansion in our understanding of solute and water kinetics that allowed 
for successful application of this mode of dialysis to acute kidney injury and end-stage renal 
disease (ESRD)2-10. This, in addition to the development of indwelling catheter that provided 
access to peritoneal cavity at will and standardization of the composition of dextrose-based 
dialysate culminated in the introduction of continuous ambulatory PD in 1976 (Figure 1)11-13. 
This was followed by changes in connectology to reduce the risk of infections, the 
introduction of volumetric cyclers, and several alternatives to conventional glucose-based 
PD solutions13-16. In this review, we highlight the major developments in the application of 
PD for the treatment of ESRD.  
Utilization and Outcomes with Peritoneal Dialysis 
 The early experience with PD raised numerous concerns whether the therapy was a 
viable alternative to in-center hemodialysis for the long-term treatment of ESRD. These 
included but were not limited to high risks of infections, inadequate clearance of small 
solutes, and deterioration of peritoneal health resulting in ultrafiltration failure, which 
together led to shorter time on therapy and higher risk for death compared to in-center 
hemodialysis13, 17-19. This led a leading nephrologist to retort in the 1980s that PD is a 
“second-class therapy for second-class patients by second-class doctors”. In part driven by 
these concerns, starting from the mid-1990s the proportion of patients with ESRD treated 
with PD progressively declined in many parts of the world20, 21.  
 Yet, the greatest improvements in the clinical application of PD occurred at the same 
time as a progressively smaller proportion of patients were utilizing the therapy.  In the 
decade starting from the mid-1990s, there was a significantly larger reduction in risk for 
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death for patients starting with PD around the world than for those undergoing in-center 
hemodialysis (Table 1)22-29. As a result, virtually all studies indicate PD and in-center 
hemodialysis now provide similar short (1- or 2-year) or long-term (up to 5 years) survival 
(Table 1)23-25, 29-31.  Furthermore, there has been a significant reduction in risk of patients 
treated with PD transferring to in-center hemodialysis in the United States indicating a 
lower risk of therapy-related complications32. These improvements have significant 
implications as they allow patients to receive treatment with a renal replacement therapy 
best suited to their values, expectations, and lifestyles, and nations the flexibility to 
incentivize dialysis modalities that allow them to offer cost-effective treatment given 
increasing budgetary constraints.  
Public Policy Changes to Increase PD Utilization 
 The relative costs of hemodialysis and PD vary around the world{Karopadi, 2013 #1}. 
In most developing countries and many developing countries societal costs with PD are 
lower providing impetus to these jurisdictions to enact public policy that promotes the use 
of a cheaper therapy{Karopadi, 2013 #1}. This is important as it has long been recognized 
that non-medical factors, including reimbursement, are the primary determinants of the 
proportion of ESRD patients treated with PD in any region of the world33, 34. With a backdrop 
provided by recent studies that PD provides equivalent survival to in-center hemodialysis, 
several countries around the world have introduced changes to increase PD utilization to 
leverage its lower costs to the health-system35. In the United States, an expanded 
prospective payment system became effective in 2011, which includes the cost of 
parenteral dialysis-related medications in capitated payments made for each dialysis 
treatment36, 37. Since PD patients require a significantly lower dose of erythropoiesis 
stimulating agents to achieve any given hemoglobin level, this policy change offers a 
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significant financial incentive to a greater use of PD38. In Thailand, the government adopted 
a “PD-First” approach in 2008 as part of its universal health coverage scheme, as in Hong 
Kong, under the aegis of which dialysis services will be paid for only if the patient is treated 
with PD, given its lower cost39. Finally, China has been rapidly expanding access to renal 
replacement therapy to its population and has a policy that encourages the use of PD 
without mandating it35. Each of these three countries has seen an unprecedented expansion 
in the use of PD. The growth in the United States has been so rapid (Figures 1 and 2) that 
the dominant manufacturer was not able to increase the supply of dialysate to meet the 
increasing demand leading to rationing of solutions in 201440. The shortage has abated but 
has not been completely eliminated.  
Rethinking Care Delivery to Increase Dialysis Treatment Options for Patients 
 An important barrier to a greater use of PD is that many patients with ESRD are 
unaware that dialysis can be done at home41, 42. Conversely, educating patients about 
treatment options is associated with a significantly higher use of PD even among patients 
who start dialysis without prior care with a nephrologist43, 44{Rioux, 2011 #2}. Even when 
practices make comprehensive modality education programs available, many patients start 
renal replacement therapy with little or no prior care by a nephrologist. These late-referred 
patients invariably start treatment with in-center hemodialysis with a central venous 
catheter45, 46. Even though “urgent-start” PD has been performed for decades, a growing 
number of centers around the world have developed these programs both to increase the 
use of PD and reduce the proportion of patients that start dialysis with a central venous 
catheter47-55. Successful implementation of “urgent-start” PD requires (1) the ability to 
educate late-referred patients on short notice about treatment options; (2) place PD 
catheters in a timely manner; and (3) offer intermittent PD in a hospital or dialysis facility up 
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until the patient can be trained to perform treatments safely at home56. A large number of 
case-series have reported successful implementation of “urgent-start” PD without an 
increase in incidence of leaks or other therapy-related mechanical complications47-55. 
 The elderly or the disabled is another group of patients that have significantly lower 
use of PD, even though many such patients would prefer treatment at home57. Many 
programs have long used family members to help patients with PD58. Several countries have 
extended this concept to include a visiting nurse to help patients with PD at home57, 59-62. 
Some of these patients require assistance only for a short-period of time61. Observational 
studies suggest that patients undergoing assisted PD have similar rates of bacterial 
peritonitis as with self-care PD and similar patient-reported outcomes and hospitalization as 
with in-center hemodialysis59, 62, 63.  
Finally, racial/ethnic minorities in the United States have a significantly lower use of 
home-based dialysis therapies64.  It is imperative to further study this to ensure all patients 
have equal access to all dialysis modalities without regard to their race/ethnicity.  
Improved Understanding of Peritoneal Physiology and Pathophysiology  
The primary goal of dialysis is to remove water and uremic solutes, and the 
effectiveness of their removal is an important determinant of outcomes of patients treated 
with PD65, 66. Recent studies have expanded our understanding of solute and water transfer 
across the peritoneum some of which could be leveraged for increasing the efficiency of PD.  
Aquaporins in the Peritoneum 
The water channel aquaporin-1 is constitutively expressed in endothelial cells lining 
peritoneal capillaries67. It is a member of a highly conserved family of water channels that 
are organized as homotetramers, with each monomer containing a central pore that 
facilitate the movement of water across the lipidic membranes 68. The deletion of Aqp1 in 
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mice results in 70% decrease in solute-free ultrafiltration, 50% decrease in cumulative 
ultrafiltration, and abolition of sodium sieving69, 70.  Indeed, glucose is effective as an 
osmotic agent because of the presence of aquaporin-1 in peritoneal endothelial cells71.  
Investigators are currently examining aquaporin-1 as a therapeutic target to increase 
ultrafiltration with PD. High-dose dexamethasone increases aquaporin-1 expression in 
peritoneal capillaries of rodents resulting in enhanced free-water transport and 
ultrafiltration72. Steroids may be efficacious in humans as illustrated by comparing 
ultrafiltration in patients before and after kidney transplantation73. Another potential agent 
is an arylsulfonamide, AqF026, the first pharmacological agonist of aquaporin-1 that 
interacts with an intracellular loop involved in the gating of the channel74. It enhances 
aquaporin-mediated water transport and net ultrafiltration in rodents. These two examples 
give hope for the possibility of developing pharmacologic therapies targeting aquaporin-1 to 
enhance ultrafiltration with PD.   
Intra-peritoneal inflammation 
There is increasing evidence that differences in chronic intraperitoneal inflammation, 
particularly interleukin-6 production by mesothelial and resident cells in the peritoneum, 
are primarily associated with differences in peritoneal solute transfer rate, which are in turn 
strongly associated with PD clinical outcomes65, 66, 75-78. Consistent with this, genetic variants 
associated with higher interleukin-6 production are associated with higher peritoneal solute 
transfer rate79, 80.  
In addition to chronic inflammation, episodes of peritonitis are associated with acute 
increases in intraperitoneal inflammation resulting in higher peritoneal solute transfer rates 
and lower ultrafiltration81. Studies in rodents suggest that locally released vasoactive 
substances, particularly nitric oxide, may mediate the increase in peritoneal solute transfer 
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rate82-84. Pharmacological inhibition or genetic deletion of the endothelial nitric oxide 
synthase significantly attenuates intraperitoneal inflammation in animals with peritonitis 
and the associated change in peritoneal solute transfer rate and ultrafiltration83.  
These findings point to potential therapeutic targets to be explored in the future to 
improve PD efficiency. 
Structural and Functional Changes over time 
Prolonged treatment with PD is associated with structural (fibrosis, angiogenesis, 
hyalinizing vasculopathy) and functional (increased peritoneal solute transfer rate, 
ultrafiltration failure) changes85. One of the most serious complications of long-term PD is 
encapsulating peritoneal sclerosis, a rare complication characterized by an exaggerated 
fibrogenic response of the peritoneum86, 87.  Studies suggest that peritoneal ultrafiltration 
capacity decreases prior to the clinical manifestation of encapsulating peritoneal sclerosis88, 
89 and that the primary mechanism is reduction in osmotic conductance (ultrafiltration 
volume for a given osmotic gradient) that is related to the increased collagen fiber density in 
the interstitium86. 
The mechanisms of peritoneal fibrosis remain debated. Progressive fibrosis is 
characterized by the release of growth factors such as TGF-β1, resulting in the accumulation 
of α-smooth muscle actin myofibroblasts in the peritoneum85, 90. Several in vitro and in vivo 
studies indicated that myofibroblasts are derived from mesothelial cells through epithelial-
mesenchymal-transition91-94, in which epithelial cells lose their polarity and differentiation, 
gain migratory and invasive properties, and become pluripotent mesenchymal stem cells 
that differentiate into fibroblasts. Consistent with studies questioning the role of epithelial-
mesenchymal transition in renal fibrosis95-97, Chen et al98 recently applied lineage-tracing 
technology in several models of peritoneal fibrosis and showed that submesothelial 
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fibroblasts – and not mesothelial cells via epithelial-mesenchymal transition - are the major 
precursors of myofibroblasts.  
These improvements in our understanding of the mechanisms involved in changes in 
the peritoneum with long-term PD hold hope that future therapies may allow us to 
ameliorate them. As an example, post-hoc analysis of a recent randomized controlled trial 
suggests that patients treated with biocompatible PD solutions may not have the increase in 
peritoneal solute transfer rate after the first month of therapy as seen with conventional PD 
solutions99, 100.  Observational studies have also raised the possibility that inhibitors of renin-
angiotensin-aldosterone system may ameliorate change in peritoneal solute transfer 
capacity over time{Kolesnyk, 2009 #3}; the beneficial effect of these drug classes, however, 
has not been tested in clinical trials. 
Cardiovascular Risk Modification in PD patients  
About 40-60% of deaths in PD patients are associated with cardiovascular events101; 
even more can be considered indirectly related if the link between cardiovascular disease, 
inflammation and frailty leading to debilitation, transfer to hemodialysis, and treatment 
withdrawal are considered77, 102-104. Registry analyses suggest that PD patients may have a 
higher risk of myocardial infarction compared to hemodialysis101, 105. This section is focused 
on non-conventional cardiovascular risk factors, with emphasis on modification by 
treatment with PD (Figure 4). A more comprehensive evaluation of evidence of 
cardiovascular risk factors is included in recently published clinical practice guidelines106, 107. 
Importance of metabolic risk factors and the role of glucose-sparing regimens 
The most obvious risk factors exacerbated by PD are metabolic, related to systemic 
glucose absorption from the dialysate. They include worsening dyslipidemia, insulin 
resistance and metabolic syndrome, and weight gain108-114. Yet, the evidence that they 
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translate into significantly worse outcomes for PD patients is variable. For example, the 
greater weight gain with PD compared to hemodialysis is unclear. Patients gain weight after 
starting PD, and this is closely mirrored by an increase in total cholesterol and fat mass. 
However, in many circumstances this weight gain reflects catch-up of the pre-dialysis loss 
108, 115. This also happens with hemodialysis and a large study found that the risk of 
significant weight gain is lower with PD115. For patients undergoing maintenance dialysis, 
the greater nutritional risk is being underweight and in this context additional calories from 
the dialysate could be advantageous116, 117; what is less clear is whether the lower death risk 
with larger body size consistently observed among patients undergoing hemodialysis is seen 
with PD118. This may be influenced by other regional factors as the risk or benefit of being 
obese in PD varies between national registries, being harmful in Australasia and neutral or 
advantageous in the United States and Brazil115, 119-121.  
One potential shortcoming of the registry analyses is the use of body mass index as 
surrogate for obesity which may under-estimate fat gain in PD patients; the preferred use of 
waist circumference in defining metabolic syndrome is also hard to validate in PD patients in 
whom abdominal girth measurements are influenced by intra-abdominal fluid. Equally, 
measuring insulin resistance in a patient who is never fasting because of continuous glucose 
absorption presents problems. This may explain the inconsistencies between studies linking 
metabolic syndrome in PD to worse outcomes111, 122, 123.  Again the role of treatment 
modality varies, as new-onset diabetes is less common in Chinese patients treated with PD 
than hemodialysis, and in either dialysis modality much less than for newly transplanted 
patients124, 125. What at first sight may be an obvious modality-specific risk factor for 
cardiovascular disease, i.e. systemic glucose absorption, turns out to be much less clear. 
12 
 
Regardless of these inconsistencies, there are now several studies showing that 
these risk factors are modifiable, although none of the trials are sufficiently powered to 
address hard endpoints. Glucose sparing solutions have been developed, such as amino-acid 
and icodextrin. In non-diabetics icodextrin used in the long exchange prevents non-fluid 
(presumed fat) weight gain and improves insulin resistance126-128. In diabetics, including 
when in combination with amino-acid solutions, icodextrin improves glycemic control and 
lipid profiles129-131. Poor glycemic control is associated with worse outcomes in diabetic PD 
patients132, 133.  
Given the concern of increased risk of myocardial infarction in PD patients the lack of 
evidence that statins can reduce this is disappointing134. Interestingly a pre-specified 
subgroup analysis of the SHARP study, the only trial to include PD patients, found a non-
significant but potentially important risk reduction suggesting that these patients may be 
different and worthy of further investigation135. 
Residual Kidney Function 
Residual kidney function is strongly associated with better survival in studies of both 
PD and hemodialysis136, 137. In the CANUSA study every 250 ml higher urine volume per day 
translated into a 36% lower 2-year mortality136. Evidence suggests that PD is associated with 
better preservation of residual kidney function compared to hemodialysis, typical reported 
rates of loss in clearance per month being 0.25-0.28 and 0.30-0.40 ml/min/1.73m2, 
respectively138-143; the mechanism is still debated but is likely in part the avoidance of 
intravascular volume depletion which occurs more frequently with hemodialysis144. Cohort 
studies and controlled trials find that in patients undergoing PD the rate of loss of kidney 
function could be slowed with avoidance of volume depletion, use of blockers of renin-
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angiotensin-aldosterone system, and the use of diuretics (urine volume and sodium loss)142, 
143, 145, 146. 
The most studied intervention to maintain residual kidney function is the use of 
biocompatible solutions. Biocompatible solutions avoid the need for sterilizing glucose at 
higher pH so limiting the formation of glucose degradation products and thus avoiding their 
associated toxicity. The balANZ study demonstrated that these solutions delay the time to 
anuria, and slow the rate of loss of clearance from 0.28 to 0.22 ml/min/1.73m2/month147. 
Subsequent meta-analyses have confirmed this observation140, 148. 
Volume management  
As already alluded to, volume depletion puts residual kidney function at risk but 
equally volume excess is detrimental. Hypertension in patients healthy enough to be wait-
listed for transplant is associated with worse survival and there is a growing body of 
evidence from bioimpedance data that over-hydration predicts worse survival149, 150. In 
anuric patients the ultrafiltration performance of the peritoneum becomes critical and daily 
net fluid removal of < 750-1000 ml is associated with higher mortality151, 152. There is 
evidence that automated PD and icodextrin use can improve the risks associated with fast 
peritoneal solute transfer rate66, 153, 154. 
The fluid status of PD patients is no worse on average than for hemodialysis patients 
pre-dialysis, but that the distribution of fluid is likely different144. Hypoalbuminaemia is 
more common with PD due to the additional peritoneal protein losses and is a reflection of 
their largely independent systemic and intraperitoneal inflammatory states77, 155. 
Intravascular plasma volume is typically normal in PD, even when excess fluid associated 
with hypoalbuminemia is present, indicating it being in the interstitial compartment156. This 
means that normalizing fluid status runs the risk of plasma volume depletion, hypotension, 
14 
 
and faster loss of residual kidney function. A recent trial using bioimpedance to support 
clinical decision making found that fluid status was very stable in PD patients with residual 
kidney function whereas the challenge in anuric patients was how to reduce volume status 
so that extracellular fluid was reduced in parallel with the loss in lean body tissue157. The 
only intervention that achieved this was an increase in glucose prescription. As things stand 
clinicians need to exercise caution and clinical judgment in setting target weights. 
Peritonitis 
Peritonitis continues to be a major cause of morbidity and mortality in PD patients 
globally101, 158, 159. Depending on the underlying causative organism, PD-related peritonitis is 
complicated by relapse in 3-20% (14% overall), catheter removal in 10-88% (22% overall), 
permanent hemodialysis transfer in 9-74% (18% overall), and death in 0.9-8.6% of cases (2-
6% overall)160-171. Following a single episode of peritonitis, the risks of death due to 
infection, cardiovascular disease and dialysis withdrawal are markedly increased in the first 
month and continue to remain significantly elevated for up to 6 months afterwards103. 
Severe and/or repeated peritonitis episodes may also culminate in sufficient damage that 
precludes successful PD and, rarely, encapsulating peritoneal sclerosis172, 173. The 
complication imposes a heavy financial burden on the healthcare system with one health 
economics analysis estimating the average cost of peritonitis-related hospitalization to be of 
the order of  $3100174. Finally, concern about the risk of PD peritonitis represents one of the 
most important patient-related barriers to the greater uptake of PD175.  
Nevertheless, peritonitis is a preventable condition and there is abundant evidence 
that infection rates around the world have decreased considerably over time176. Single 
center observational studies from different parts of the world, as well as a multi-national 
national registry studies have reported that the rates of PD-related infections have steadily 
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decreased over the last 10-20 years158, 177-182. Although this reduction has been most 
apparent for Gram-positive infections, significant reductions have also been reported for 
Gram-negative peritonitis158, 177-182. These reductions have been variously attributed to the 
use of twin bag disconnection systems, implementation of mupirocin chemoprophylaxis 
protocols, topical exit site application of gentamicin, co-prescription of nystatin or 
fluconazole with antibiotic therapy, improved training of PD patients and/or staff, and 
better identification and targeting of peritonitis risk factors177, 183-190. Within Australia, 
country-wide PD-related peritonitis rates fell significantly by 37% over a 5-year period from 
0.62 episodes per patient-year in 2008 to 0.39 episodes per patient-year in 2013 following a 
concerted, multi-disciplinary and multi-pronged national peritonitis reduction campaign 
involving quarterly audit and feedback of individual unit peritonitis rates, prioritization of 
peritonitis prevention trials by the Australasian Kidney Trials Network, updating national 
clinical practice guidelines on peritonitis, launching peritonitis guideline implementation 
projects, publishing of a call to action paper, establishment of a PD Academy to provide PD 
training to junior nephrologists and nursing staff, and development of a Home Dialysis 
Network to support home dialysis patients (http://homedialysis.org.au/)191-196.  
Despite these improvements, there remains a wide and unacceptable variation in 
reported rates from different countries, ranging from 0.06 episodes/ year in Taiwan to 1.66 
episodes/ year in Israel197. Furthermore, up to 20-fold variation in peritonitis rates has been 
reported between centers within individual countries, such as Australia (Figure 5)171, 191, 
Austria198, Scotland199, and the United Kingdom200. The sources of these variations have not 
been adequately investigated but may relate to center-related factors, such as unit size, 
topical antibiotic prophylaxis or PD training practices158, 189, 198, 199, 201, 202. A previous national 
survey found highly variable and generally poor compliance of centers with clinical practice 
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guidelines for prevention of peritonitis203. More recently, an ANZDATA Registry analysis 
found that the wide variation in peritonitis rates across Australian dialysis centers was 
decreased by 16% after adjustment for patient characteristics (e.g. demographics, 
comorbidities), and was reduced by a further 34% after accounting for a limited number of 
center-level characteristics, such as unit size, proportion of dialysis patients treated with PD, 
use of anti-fungal chemoprophylaxis, icodextrin use, performance of peritoneal 
equilibration tests, cycler use and propensity to admit patients with PD-related peritonitis to 
hospital204. This observation suggests that center practices play a dominant role in 
mediating between-center variation in peritonitis rates. Similarly, unacceptable variations in 
the outcomes of peritonitis treatment have been significantly associated with observed 
deviations in practice from clinical practice guidelines205. 
The key message from these studies is that although peritonitis rates are generally 
improving globally over time, there have been marked and unacceptable variations in 
peritonitis rates and outcomes between centers in many countries. This variation is 
explained to a large extent by variation in center practices, with poorer results generally 
being observed in units that deviate from evidence-based best practice recommendations 
(and not infrequently from their own unit policies)205. Key strategies for correcting this 
ubiquitous problem in PD include benchmarking of PD center peritonitis rates and outcomes 
through the establishment of national PD peritonitis registries within each country, 
alignment of PD practice in each center with clinical practice guidelines, strengthening of 
clinical governance within each unit and adoption of a whole-of-unit approach to 
continuous quality improvement, including root cause analysis of all cases of peritonitis 
within each center to identify areas for improvement197, 206. 
Future Directions 
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 Despite tremendous progress on multiple fronts, patients with end-stage renal 
disease carry a heavy burden of disease and treatment. We owe to the patients to continue 
to reconfigure health care delivery to better match dialysis modality to patients’ desires, 
improve the efficiency of therapy without putting a greater burden on patients, reduce 
cardiovascular risk, and better apply lessons learnt from research in clinical practice (Table 
2).   
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Figure Legends 
Figure 1: Major landmarks in the development of peritoneal dialysis as a treatment for 
end-stage renal disease (1923-’78). Abbreviations, AKI: acute kidney injury; 
PD, peritoneal dialysis. 
Figure 2:  Secular trends in the number of patients treated with peritoneal dialysis in 
the United States (1996-2013). (1A) The number of patients treated with 
peritoneal dialysis by 90 of start of maintenance dialysis; (1B) Point prevalent 
counts of the number of patients treated with peritoneal dialysis as of 
December 31 of each calendar year.  
Figure 3: Secular trends in the proportion of patients undergoing maintenance dialysis 
treated with peritoneal dialysis in the United States (1996-2013). The blue 
line represents the proportion of all patients undergoing maintenance 
dialysis treated with peritoneal dialysis 90 days from the date of first dialysis 
and the red line represents the proportion of all patients undergoing 
maintenance dialysis on December 31 of any calendar year.  
Figure 4: Overview of interrelationships between modality-specific factors that may 
contribute to the cardiovascular risk of patients undergoing peritoneal 
dialysis 
Figure 5: Center-specific PD-related peritonitis rates (incidence rate ratios) in Australia 
during the periods 2004-2008 (open triangles) and 2009-2013 (solid circles) 
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Table 1: Summary of studies from around the world demonstrating greater reductions in risk for death in patients treated with peritoneal dialysis compared 
to in-center hemodialysis  
Author, 
Publication Year 
Country/Region Eras Mortality Trends by Modality Trends in comparative survival 
Mehrotra, ‘0722 United States 1996-1997 
1998-1999 
2000-2001 
2002-2003 
Compared to 1998-1999, the adjusted hazards for 
patients starting peritoneal dialysis to die or 
transfer to hemodialysis within 12 months was 17% 
lower; no significant difference over time for 
patients starting hemodialysis 
 
Mehrotra, ‘1123 United States 1996-1998 
1999-2001 
2002-2004 
 The adjusted hazards ratio for death (PD/HD) 
were 1.07 (1.04, 1.11), 1.08 (1.06-1.11), and 1.03 
(0.99, 1.06) respectively 
Chang, ‘1224 Taiwan 1997-2001 
2002-2006 
 The adjusted hazards ratio for death (PD/HD) 
were 1.33 (1.21, 1.46), and 0.99 (0.87, 1.14) 
respectively 
Yeates, ‘1225 Canada 1991-1995 
1996-2000 
2001-2004 
 The adjusted hazards ratio for death (PD/HD) 
were 1.08 (1.02, 1.15), 1.13 (1.07, 1.20), and 0.99 
(0.92, 1.06), respectively 
Heaf, ‘1426 Denmark 1990-1994 
1995-1999 
Adjusted death risk for patients starting 
hemodialysis and peritoneal dialysis in 2005-2010 
The adjusted hazards ratio for death (PD/HD) 
were 0.95 (0.85, 1.06), 0.90 (0.82, 1.00), 0.84 
52 
 
2000-2004 
2005-2010 
was 30% (95% confidence interval, 13-37%) and 
46% (95% confidence interval, 37-51%) lower 
compared to patients who started hemodialysis in 
1990-1994  
(0.77, 0.92), and 0.80 (0.71, 0.89), respectively 
Marshall, ‘1527 Australia and 
New Zealand 
1998-2002 
2003-2007 
2008-2012 
Compared to 1998-2002, adjusted death risk for 
patients starting hemodialysis in 2008-2012 was 
21% lower (95% confidence interval, 15-26%) 
compared to 1998-2002; for patients starting PD, 
27% lower (95% confidence interval, 11-23%)  
 
Ryu, ‘1528 South Korea Each year, 
from 2005 
through 
2008 
Compared to 2005, in 2008 adjusted death risk for 
patients starting hemodialysis was 15% lower (95% 
confidence interval, 9-20%) and starting peritoneal 
dialysis 25% lower (95% confidence interval, 16-
34%)  
Among patients who started dialysis in 2008, no 
significant difference in risk for death for patients 
treated with HD, compared to those treated with 
PD (adjusted hazards ratio,  0.91 (0.82, 1.00)) 
van de 
Luijtgaarden, ‘1529 
Europe (ERA-
EDTA Registry) 
1993-1997 
1998-2002 
2003-2007 
Compared to 1993-1997, adjusted death risk for 
patients starting hemodialysis in 2003-2007 was 
18% lower (95% confidence interval 16-20%) and 
starting peritoneal dialysis was 36% lower (95% 
confidence interval, 33-39%) 
The adjusted hazards ratio for death (PD/HD) 
were 1.02 (0.98, 1.06), 1.00 (0.96, 1.03), and 0.91 
(0.88, 0.95), respectively 
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Table 2: Important thematic areas in need for further research 
Utilization and Outcomes with Peritoneal Dialysis 
• Approaches to modality education that optimize decision support and reduce decisional conflict  
• Clinical outcomes of late-referred patients starting treatment with PD (“urgent-start” PD) and in-
center hemodialysis with central venous catheter 
• Comparative effectiveness of home and in-center dialysis for end-of-life care for patients with 
end-stage renal disease 
• Understanding reasons for the low utilization of PD by racial/ethnic minorities and tailored 
interventions to overcome barriers 
• Adequately powered studies comparing a broad range of patient-reported outcomes with 
different dialysis modalities, including effect-modification by cultural differences 
Peritoneal Physiology and Pathobiology 
• Mechanisms of osmosis, choice of solutions, new osmotic agents, combination of different types 
of osmotic agents 
• Biomarkers of peritoneal solute and water transfer - at baseline and over time on PD: genetics, 
proteomics, metabolomics 
• Nanoparticles, new indications for PD: intoxications (liposome supported peritoneal dialysis for 
intoxication and metabolic disorders 
• Getting hematopoietic stem cells from patients on PD  
• Identification of other molecular counterparts of additional transport structures, e.g. the small 
pores 
Cardiovascular Risk with Peritoneal Dialysis 
• Validation of more practical approach to defining metabolic syndrome for PD patients 
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• Better understanding of high risk cardiovascular risk phenotypes to include interactions with 
diabetes, gender and ethnicity 
• Adequately powered study to test the benefit of statins  
• Trials to evaluate additional strategies for preserving residual kidney function  
• Trials addressing the risk/benefit of preserving residual kidney function while optimizing volume 
status and blood pressure management, including further evaluation of technologies to evaluate 
fluid status at the bedside. 
Peritonitis 
• Determining which PD training methods, curricula and structured assessment methods lead to 
better peritonitis rates 
• Determining whether structured periodic retraining after initial baseline training leads to a 
reduction in peritonitis rates 
• Development and evaluation of rapid (within hours) organism identification methods in PD-
related peritonitis. 
• Does use of continuous vs. intermittent intraperitoneal antibiotics for peritonitis treatment lead 
to better peritonitis outcomes? 
• Does temporary conversion of automated PD patients to continuous ambulatory PD during 
peritonitis treatment lead to better outcomes compared with leaving patients on automated 
PD? 
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